CLARITY-PanTumor01: A phase 2 trial of the claudin 18.2-specific antibody-drug conjugate AZD0901 (CMG901) in patients with CLDN18.2-expressing advanced solid tumors.

被引：0
|
作者：
Raufi, Alexander G.
Goyal, Lipika
Smyth, Elizabeth
Szekeres, Philip
Petrone, Marcella
Hobson, Rosalind
Thress, Kenneth
Origuchi, Makoto
Nehra, Jyoti
Brown, Jessica S.
Kumar, Rakesh
Grenga, Italia
Barker, Laura
Janjigian, Yelena Y.
Shitara, Kohei
机构：
[1] Brown Univ, Lifespan Canc Inst, Rhode Isl Hosp, Div Hematol Oncol,Warren Alpert Med Sch, Providence, RI USA
[2] Stanford Sch Med, Div Oncol, Palo Alto, CA USA
[3] Oxford NIHR Biomed Res Ctr, Churchill Hosp, Oxford, England
[4] AstraZeneca, Cambridge, England
[5] AstraZeneca, Waltham, MA USA
[6] AstraZeneca, Gaithersburg, MD USA
[7] AstraZeneca, Global Med Dev, Oncol R&D, Cambridge, England
[8] Mem Sloan Kettering Canc Ctr, New York, NY USA
[9] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3163
引用
收藏
页数：1
相关论文
共 9 条
  • [1] CMG901, a Claudin18.2-specific antibody-drug conjugate, for the treatment of solid tumors
    Xu, Gang
    Liu, Wei
    Wang, Ying
    Wei, Xiaoli
    Liu, Furong
    He, Yanyun
    Zhang, Libo
    Song, Qin
    Li, Zhiyao
    Wang, Changyu
    Xu, Ruihua
    Chen, Bo
    CELL REPORTS MEDICINE, 2024, 5 (09)
  • [2] A phase 1 trial of claudin 18.2-specific antibody-drug conjugate CMG901 in patients with advanced gastric/gastroesophageal junction cancer.
    Xu, Rui-Hua
    Ruan, Dan-Yun
    Zhang, Dong-Sheng
    Liu, Fu-Rong
    Luo, Su-Xia
    Zhuang, Zhi-Xiang
    Wang, Zhen-Ning
    Liu, Fu-Nan
    Zhang, Yan-Qiao
    Yang, Jian-Wei
    Chen, Zhen-Dong
    Wang, Yong-Sheng
    Wang, Jun-Ye
    Liang, Xiao-Hua
    Wu, Xiao-Jie
    Zheng, Yu-Long
    Liu, Jian
    Shi, Xi
    Liu, Wei
    Chen, Bo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (36_SUPPL) : 434420 - 434420
  • [3] A phase 1 trial of claudin 18.2-specific antibody-drug conjugate CMG901 in patients with advanced gastric/gastroesophageal junction cancer.
    Xu, Rui-Hua
    Ruan, Dan-Yun
    Zhang, Dong-Sheng
    Liu, Fu-Rong
    Luo, Su-Xia
    Zhuang, Zhi-Xiang
    Wang, Zhen-Ning
    Liu, Fu-Nan
    Zhang, Yan-Qiao
    Yang, Jian-Wei
    Chen, Zhen-Dong
    Wang, Yong-Sheng
    Wang, Jun-Ye
    Liang, Xiao-Hua
    Wu, Xiao-Jie
    Zheng, Yu-Long
    Liu, Jian
    Shi, Xi
    Liu, Wei
    Chen, Bo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [4] A phase 1a dose-escalation, multicenter trial of anti-claudin 18.2 antibody drug conjugate CMG901 in patients with resistant/refractory solid tumors.
    Xu, Rui-hua
    Wei, Xiaoli
    Zhang, Dongsheng
    Qiu, Miaozhen
    Zhang, Yang
    Zhao, Hongyun
    Chen, Bo
    Yan, Joy
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 352 - 352
  • [5] CLARITY-Gastric 01: A randomized phase 3 study of AZD0901, a Claudin18.2 (CLDN18.2)-targeted antibody-drug conjugate, in second- or later-line (2L+) advanced gastric or gastroesophageal junction cancer (GC/GEJC).
    Janjigian, Yelena Y.
    Shitara, Kohei
    Elimova, Elena
    Zhang, Jun
    Chen, Ming-Huang
    Smyth, Elizabeth Catherine
    Lee, Jeeyun
    Miao, Rui
    Liu, Silver
    Holmblad, Marielle
    Xu, Rui-Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS507 - TPS507
  • [6] CLARITY-Gastric 01: A randomised phase III study of AZD0901, a Claudin18.2 (CLDN18.2)-targeted antibody-drug conjugate, in second- or later-line (2L+) advanced gastric or gastroesophageal junction cancer (GC/GEJC)
    Shitara, K.
    Janjigian, Y. Y.
    Elimova, E.
    Zhang, J.
    Chen, M-H.
    Smyth, E.
    Lee, J.
    Miao, R.
    Liu, S.
    Holmblad, M.
    Xu, R-H.
    ANNALS OF ONCOLOGY, 2024, 35 : S196 - S197
  • [7] Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label single-arm, phase 1 trial
    Ruan, Dan-Yun
    Liu, Fu-Rong
    Wei, Xiao-Li
    Luo, Su-Xia
    Zhuang, Zhi-Xiang
    Wang, Zhen-Ning
    Liu, Fu-Nan
    Zhang, Yan-Qiao
    Yang, Jian-Wei
    Chen, Zhen-Dong
    Wang, Yong-Sheng
    Wang, Jun-Ye
    Liang, Xiao-Hua
    Wu, Xiao-Jie
    Zheng, Yu-Long
    Liu, Jian
    Shi, Xi
    Kumar, Rakesh
    Liu, Wei
    Chen, Bo
    Zhang, Dong-Sheng
    Xu, Rui-Hua
    LANCET ONCOLOGY, 2025, 26 (02): : 227 - 238
  • [8] A phase 1/2 study of LM-302, an anti-claudin 18.2 (CLDN18.2) antibody-drug conjugate in patients with advanced gastric/gastroesophageal junction cancer.
    Bai, Chunmei
    Xue, Junli
    Zheng, Yi
    Sun, Meili
    Ying, Jieer
    Zhou, Fuxiang
    Yu, Yiyi
    Sun, Yuping
    Xing, Ligang
    Zhang, Yanqiao
    Wen, Jinhua
    Xiong, Jianping
    Wu, Heshui
    Yang, Xiuli
    Wan, Lixin
    Guo, Shiwei
    Zhao, Rusen
    Zhu, Zhizhen
    Gong, Zhihua
    Li, Jin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Anti-claudin 18.2 (CLDN18.2) antibody-drug conjugate (ADC) IBI343 in patients (pts) with solid tumors and gastric/ gastro-esophageal junction adenocarcinoma (G/GEJ AC): A phase study
    Liu, J. J.
    Yu, X.
    Zhang, J.
    Yang, J.
    Yue, J.
    Sun, Y.
    Pan, Y.
    Sun, M.
    Qin, Y.
    Shen, L.
    Song, R.
    Ruan, J.
    Zhou, A.
    Mou, Y.
    Liu, Z.
    Liu, Z.
    Morris, M.
    Aghmesheh, M.
    Tazbirkova, A.
    Zhou, H.
    ANNALS OF ONCOLOGY, 2024, 35 : S160 - S160
1